| Dr Harvinder S Dod, MD | |
|
700 W Grove St, El Dorado, AR 71730-4416 | |
| (870) 875-5540 | |
| (870) 875-5548 |
| Full Name | Dr Harvinder S Dod |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 29 Years |
| Location | 700 W Grove St, El Dorado, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699983635 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ouachita County Medical Center | Camden, AR | Hospital |
| Medical Center Of South Arkansas | El dorado, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hmdod Llc | 2961837216 | 2 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588654016 PECOS PAC ID: 4082528955 Enrollment ID: O20031219000706 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346230968 PECOS PAC ID: 4082528955 Enrollment ID: O20040115000431 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | South Arkansas Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427018704 PECOS PAC ID: 0749273670 Enrollment ID: O20040406001623 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Ouachita County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346354826 PECOS PAC ID: 4587641055 Enrollment ID: O20080813000469 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Arkansas Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774630 PECOS PAC ID: 3274681341 Enrollment ID: O20090501000014 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Mercy Clinic Fort Smith Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023346202 PECOS PAC ID: 3870668510 Enrollment ID: O20100304000134 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | South Arkansas Cardiology, P.l.l.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568567188 PECOS PAC ID: 2264699479 Enrollment ID: O20120131000149 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881967305 PECOS PAC ID: 6103085295 Enrollment ID: O20120308000726 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Sark Opl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558893776 PECOS PAC ID: 7810261088 Enrollment ID: O20170927000871 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Entity Name | Hmdod Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316580996 PECOS PAC ID: 2961837216 Enrollment ID: O20200115001774 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harvinder S Dod, MD 700 W Grove St, El Dorado, AR 71730-4416 Ph: (870) 875-5540 | Dr Harvinder S Dod, MD 700 W Grove St, El Dorado, AR 71730-4416 Ph: (870) 875-5540 |
News Archive
United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
A new study by researchers at the Harvard T.H. Chan School of Public Health and Brown University shows that about half of US hospitals have reported reaching critical capacity since September, illustrating the scale of the coronavirus pandemic's ‘second wave' and the burden of pressure it has placed on the nation's healthcare.
New findings from The University of Texas Medical Branch at Galveston show that patients qualifying for Medicare because of a disability have the highest rates of opioid overdose deaths compared with older Medicare beneficiaries and commercial insurance beneficiaries.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.
› Verified 1 days ago
Dr. Pamela Jean Schonefeld, MD, FACP Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 620 W Grove St Ste 101, El Dorado, AR 71730 Phone: 870-862-0801 | |
Dr. Johnnie Hinton Iii, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 620 W Grove St, El Dorado, AR 71730 Phone: 501-321-9803 Fax: 501-321-0710 | |
Dr. Michael D Schonefeld, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 620 W Grove St, El Dorado, AR 71730 Phone: 501-321-9803 Fax: 501-321-0710 | |
Dr. Joseph A Deluca, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 620 W Grove St Ste 202, El Dorado, AR 71730 Phone: 870-234-7676 Fax: 870-562-2560 | |
Donald J Voelker, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 700 W Grove St, El Dorado, AR 71730 Phone: 870-875-5540 Fax: 870-864-9680 | |
Mr. Douglas William Long, ACNPC-AG Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 403 W Oak St Ste 100, El Dorado, AR 71730 Phone: 870-875-1481 Fax: 870-875-1485 | |
Daniel D Schrader, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 704 W Grove St, Suite 7, El Dorado, AR 71730 Phone: 870-864-6700 Fax: 870-864-6704 |